.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Fish and Richardson
McKinsey
Chinese Patent Office
Colorcon
Merck
AstraZeneca
Julphar
Express Scripts

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,968,976

« Back to Dashboard

Which drugs does patent 5,968,976 protect, and when does it expire?


Patent 5,968,976 protects FOSRENOL and is included in two NDAs. There have been two Paragraph IV challenges on Fosrenol.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: 5,968,976

Title: Pharmaceutical composition containing selected lanthanum carbonate hydrates
Abstract:Selected lanthanum carbonate hydrates may be administered into the gastrointestinal tract, to treat hyperphosphataemia in patients with renal failure.
Inventor(s): Murrer; Barry A (Berkshire, GB), Powell; Nigel A (Berkshire, GB)
Assignee: AnorMed Inc. (Langley, CA)
Application Number:08/913,960
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Process; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire Dev Llc
FOSRENOL
lanthanum carbonate
POWDER;ORAL204734-002Sep 24, 2014RXYesYes► Subscribe► SubscribeY TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
Shire Dev Llc
FOSRENOL
lanthanum carbonate
POWDER;ORAL204734-001Sep 24, 2014RXYesNo► Subscribe► SubscribeY TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
Shire Llc
FOSRENOL
lanthanum carbonate
TABLET, CHEWABLE;ORAL021468-004Nov 23, 2005ABRXYesYes► Subscribe► SubscribeY REDUCTION OF SERUM PHOSPHATE
Shire Llc
FOSRENOL
lanthanum carbonate
TABLET, CHEWABLE;ORAL021468-001Oct 26, 2004DISCNNoNo► Subscribe► SubscribeY REDUCTION OF SERUM PHOSPHATE
Shire Llc
FOSRENOL
lanthanum carbonate
TABLET, CHEWABLE;ORAL021468-002Oct 26, 2004ABRXYesNo► Subscribe► SubscribeY REDUCTION OF SERUM PHOSPHATE
Shire Llc
FOSRENOL
lanthanum carbonate
TABLET, CHEWABLE;ORAL021468-003Nov 23, 2005ABRXYesNo► Subscribe► SubscribeY REDUCTION OF SERUM PHOSPHATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,968,976

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9506126Mar 25, 1995
PCT Information
PCT FiledMarch 19, 1996PCT Application Number:PCT/GB96/00575
PCT Publication Date:October 03, 1996PCT Publication Number: WO96/30029

International Patent Family for Patent: 5,968,976

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0817639► SubscribeSPC/GB06/036United Kingdom► Subscribe
European Patent Office0817639► SubscribePA2008005Lithuania► Subscribe
European Patent Office0817639► SubscribePA2008005,C0817639Lithuania► Subscribe
Estonia04096► Subscribe
Estonia9700325► Subscribe
Eurasian Patent Organization000270► Subscribe
Denmark0817639► Subscribe
Germany122007000022► Subscribe
Germany69617659► Subscribe
Canada2216437► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Accenture
Johnson and Johnson
Harvard Business School
Merck
AstraZeneca
Dow
Mallinckrodt
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot